RCS - Oxford Biomedica PLC - Hardman Research: New advanced therapies era <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

12/09/2017 07:17

RNS Number : 4298Q
Oxford Biomedica PLC
12 September 2017
Hardman Research: New advanced therapies era
New advanced therapies era -OXB is a specialist advanced therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining proprietary drug candidates. OXB will also receive royalties on commercial therapies developed with its LentiVector platform. The first such therapy, also the first CAR-T therapy to ever be approved, was licensed by the FDA on 30th August 2017: tisagenlecleucel (Kymriah) is manufactured by Novartis using lentivirus vector supplied by OXB. OXB will be the first UK company to manufacture viral vector for commercial production of a licensed gene-based medicine.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/12.09.17-new-era-for-cell-and-gene-therapies.pdf
To contact us: 
Hardman & Co
35 New Broad Street
London
EC2M 1NH
Contacts:
Dr Martin Hall
mh@hardmanandco.com 
Dr Dorothea Hill
dmh@hardmanandco.com
Dr Gregoire Pave
gp@hardmanandco.com
Telephone: +44 20 7194 7622
Follow us on Twitter @HardmanandCo
www.hardmanandco.com 
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors,and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRALLFFDATILLID